Nitroglycerin Stimulates Synthesis of Prostacyclin by Cultured Human Endothelial Cells

Richard I. Levin, Eric A. Jaffe, Babette B. Weksler, and Karen Tack-Goldman, Division of Hematology-Oncology, Department of Medicine, Cornell University Medical College, New York 10021

Abstract Nitroglycerin (NTG), the agent most commonly used to treat acute angina pectoris, is a vasodilator whose mechanism of action remains unknown. We hypothesized that NTG might induce endothelial cells to synthesize prostacyclin (PGI₂), a known vasodilator and inhibitor of platelet aggregation. Therefore, cultured human endothelial cells were incubated with NTG at various concentrations for 1–3 min. PGI₂ biologic activity in the endothelial cell supernates was assayed by inhibition of platelet aggregation in vitro. The concentration of 6-keto-PGF₁α, the stable hydrolysis product of PGI₂, was measured by specific radioimmunoassay.

NTG alone significantly inhibited platelet aggregation and thromboxane A₂ synthesis only at suprapharmacologic concentrations (≥1 μg/ml). However, when NTG at clinically attainable concentrations (0.1–10 ng/ml) was incubated with endothelial cells, the endothelial cell supernates inhibited platelet aggregation in a dose-dependent manner. The inhibitor was heat labile. Radioimmunoassay of the endothelial cell supernates for 6-keto-PGF₁α demonstrated that NTG elicited dose-dependent increments in the synthesis of PGI₂ by endothelial cells, ranging from 13% at NTG 10 μg/ml to 63% at NTG 10 μg/ml (P < 0.01, n = 10). Pretreatment of endothelial cells with either aspirin (50 μM for 120 min) or the prostacyclin synthetase inhibitor 15-hydroperoxylarachidonic acid (20 μg/ml for 15 min) abolished production of the platelet inhibitory substance. Synergy between NTG and PGI₂ in the inhibition of platelet aggregation was not present at clinically attainable concentrations of NTG.

Thus, NTG at clinically attainable concentrations causes a dose-dependent increase in PGI₂ synthesis by endothelial cells. If this phenomenon occurs in vivo, the PGI₂ produced could ameliorate myocardial ischemia by causing peripheral vasodilation and decreasing cardiac work, inhibiting platelet aggregation and thromboxane A₂ synthesis, and possibly reversing coronary artery vasospasm.

Introduction Nitroglycerin (NTG) is a vasodilator of unknown mechanism which has been used clinically since 1855 for the treatment of angina pectoris (1). In addition to its vasodilating properties, NTG is an inhibitor of platelet aggregation in vitro, though only at high, suprapharmacologic concentrations (2–4). Thus, it belongs to a diverse group of agents including alcohol, dipryidamole, nitroprusside, verapamil, hydralazine, and others, which have both vasodilatory and antiplatelet activities (5–8).

It has been noted by Garratini (5) that for many of these drugs, there is a marked disparity between concentrations which inhibit platelet aggregation in vitro and therapeutic plasma levels obtained in vivo. The minimal in vitro inhibitory levels can be several orders of magnitude higher than the in vivo counterparts. Thus, if these agents inhibit platelet activity in vivo when used therapeutically, they must act indirectly. The mechanism of that action may also be responsible for the vasodilation. We hypothesized that NTG might stimulate the production of a second substance in vivo
which in turn would decrease vascular tone and inhibit platelet activity. Prostacyclin (PGI2) is now well established as a potent, naturally occurring vasodilator and platelet inhibitor (9, 10). Its properties are thus identical to the class of agents noted above. Furthermore, PGI2 is produced by endothelial cells (11). We therefore postulated that NTG acts in vivo by stimulating the production of PGI2 by endothelial cells.

This paper demonstrates that NTG induces a significant and dose-related increase in endothelial cell PGI2 synthesis in vitro; the PGI2 produced inhibits platelet function.

METHODS

Cell culture technique. Human endothelial cells were obtained from umbilical cord veins and cultured in 24-well (16 mm Diam) cluster plates (Costar, Cambridge, Mass.) as described (12, 13). Cultures were used at confluence in the second or third serial passage. Cell counts were performed as described (11, 12) and any well containing cells > ±10% of the mean cell count was rejected from further evaluation.

Human lung fibroblasts (GM 1380, Human Genetic Mutant Cell Repository, Institute for Medical Research, Camden, N. J.) were maintained in minimal essential medium (Flow Laboratories Inc., Rockville, Md.) with 20% fetal calf serum in T75 flasks until passage into 24-well cluster plates. Cultures were then used at confluence.

Treatment of endothelial cells with NTG. NTG as a sterile aqueous solution containing solely NTG (0.5 mg/ml) and lactose (4.5 mg/ml) was obtained as a gift from Eli Lilly & Co., Indianapolis, Ind. Because of the recent demonstration that NTG is adsorbed to plastic, serial 10-fold dilutions in sterile water were prepared in glass tubes immediately prior to use (14). Light-shielding was used although it has recently been shown that lactate-adsorbed, aqueous NTG solutions do not decompose in light (15).

Each monolayer of endothelial cells was washed twice with a buffer containing 10 mM Hepes (pH 7.35 at 37°C), 137 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5.5 mM glucose (buffer I). The cultures were agitated as little as possible to prevent shear-induced PGI2 production. 490 μl of this buffer and 10 μl of NTG solution were mixed to yield final NTG concentrations of 100 fg/ml to 10 ng/ml and then placed over the endothelial cell monolayer immediately after the second wash. After it was determined in preliminary experiments that maximal PGI2 release was obtained after incubation for 3 min at 37°C, all incubations were performed for 3 min at 37°C. Supernates were then removed, rapidly frozen, and then stored at −70°C until use.

In each experiment the following control incubations with endothelial cells were performed: (a) buffer I containing 20 μM sodium arachidonate (AA, Sigma Chemical Co., St. Louis, Mo.); (b) buffer alone; and (c) buffer containing 90 μg/ml lactose (the vehicle for NTG; Sigma Chemical Co.). In addition, NTG solutions were incubated in wells without endothelial cells, which had been treated identically (gelatin-coated, medium-conditioned) to those containing cultured cells. Finally in each experiment, the NTG, AA and buffer solutions were each incubated with endothelial cells which had been pretreated with either aspirin (ASA) (Sigma Chemical Co.) or 15-hydroperoxy arachidonic acid (a gift from Dr. Aaron Marcus) by methods described (16, 17).

Platelet aggregation and thromboxane B2 production. Platelet-rich plasma (PRP) was prepared from venous blood and aggregation studies performed by methods described (18). Inhibition of aggregation was quantitated either by expressing the increase in light transmission 5 min after the addition of the stimulus as a percentage of control (method A) or by determining the area under the curve from stimulus to the 5-min mark by planimetry (planimeter No. 123A, Dietzgen Corp., Des Plaines, Ill.) and expressing it as a percentage of the area under the control curve (method B) (19).

Because of the length of experiments, control aggregations were performed every 15 min in each channel to verify stability of the platelet response.

For the measurement of platelet thromboxane (TXA2) production, platelet samples were prepared by a modification of the method of Fitzpatrick and Gorman (20). 5 min after addition of the stimulus to each aggregation cuvette, a 500-μl sample was removed, immediately added to 900 μl of buffer I containing indomethacin 2 μg/ml, vortexed, and frozen in a dry ice-acetone bath at −70°C. Samples were subsequently thawed, spun at 12,500 g for 3 min and the supernates removed and stored at −70°C for testing in the radioimmunoassay (RIA) for TXB2 as described below.

Studies on the platelet inhibitory effect of NTG. Inhibition of platelet thromboxane production by NTG was studied using the following aggregating agents (expressed as final concentration in the cuvette): (a) Sodium arachidonate (Sigma Chemical Co.), 0.1–0.2 mM; (b) Collagen (Hormon-Chemie, Munich, West Germany) 0.1–1 μg/ml; (c) ADF (Sigma Chemical Co.), 1–3 μl; (d) Epinephrine (Parke-Davis & Co., Detroit, Mich.) 1–2 μM; and (e) U-44069 (Upjohn Co., Kalamazoo Mich.) 2.4–2.9 μM. The threshold aggregating concentration of each agent was determined after incubating the PRP for 1–5 min with buffer I such that the final volume after all additions was 0.5 ml. Threshold was defined as the lowest concentration which caused ≥90% increase in light transmission at 5 min. Varying concentrations of NTG were incubated with aliquots of PRP for 1–5 min. Threshold concentrations of each aggregating agent were then added and aggregation recorded.

Possible synergy between NTG and either synthetic PGI2 or 6-keto-prostaglandin (PGF1α, kindly provided by Dr. John Pike, Upjohn Co.) was studied in a similar manner by combining the agent in various concentrations before stimulation.

RIA for 6-keto-PGF1α and TXB2 conjugation and immunization. 10 mg keyhole limpet hemocyanin (Pacific Bio-Marine Laboratories Inc., Venice, Calif., Eiso = 2.49) was conjugated to 5 mg 6-keto-PGF1α (Upjohn Co.) using 10 mg 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (Sigma Chemical Co.) according to the method of Fitzpatrick et al. (21). 300 μg 6-keto-PGF1α-keyhole limpet hemocyanin conjugate was emulsified with an equal volume of Freund's complete adjuvant (Difco Laboratories, Detroit, Mich.) and injected intradermally at multiple sites into New Zealand white rabbits. After 6 wk, the rabbits were injected intradermally with 100 μg 6-keto-PGF1α-keyhole limpet hemocyanin conjugate emulsified with Freund's incomplete adjuvant (Difco Laboratories). The animals were bled 10–14 d later from the central ear artery and the serum tested. The rabbits were injected thereafter with 100 μg 6-keto-PGF1α-keyhole limpet hemocyanin conjugate in Freund's incomplete adjuvant at monthly intervals until the titers dropped.

The conjugation and immunization protocol for TXB2 antibody was similar except that the collected rabbits' blood was antiocoagulated with EDTA and 0.1 mM indomethacin at 4°C and centrifuged at 3,000 rpm for 15 min at 4°C. The plasma was removed and recalified before use.

RIA. The RIA for 6-keto-PGF1α was performed as follows. 0.1 ml of diluted [3H]6-keto-PGF1α (100 Ci/ml, New
England Nuclear, Boston, Mass.) containing 10,000 dpm and 0.1 ml of test sample (diluted when necessary with buffer I) were mixed in Eppendorf 1.5 ml polystyrene test tubes. Purity of [PH]6-keto-PGF\(_{1\alpha}\) was verified by thin-layer chromatography. 0.1 ml of anti-6-keto-PGF\(_{1\alpha}\) antisera diluted 1:30,000 with buffer II (50 mM Hepes, pH 7.5, 0.2% bovine serum albumin, and 0.02% sodium azide) was then added and the mixture incubated for 24 h at room temperature. Preliminary tests showed that this time was sufficient to yield a maximal binding of the antibody to the [PH]6-keto-PGF\(_{1\alpha}\). Formalin fixed Staphylococcus aureus cow type I (Pansorbin, Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.) were then added (100 ml of a 1% suspension) and the mixture incubated for 30 min at room temperature. The mixture was centrifuged at 2,500 rpm for 30 min. 300 ml of the total 400 ml were removed and counted in a liquid scintillation counter. A standard curve (containing 1–2,000 pg/tube of authentic 6-keto-PGF\(_{1\alpha}\)) was run with every assay as were controls to check that the S. aureus was present in excess to bind all the antibody added. Standards were assayed in triplicate and unknowns were assayed at two different dilutions, each in duplicate. The data was analyzed using the four parameter logistic method of Rodbard and Hutt (22).

50% inhibition of binding was reached at 50–60 pg and the range of sensitivity was 3–1,000 pg. Cross reactivities were as follows: PGI\(_2\)-100%; 6,15-diketo-PGF\(_{1\alpha}\)-1.3%; 6-keto-PGE\(_1\)-1.1%, 13,14-dihydro-6,15-diketo-PGF\(_{1\alpha}\)-1%, PGE\(_{1\alpha}\)-0.1%; PGE\(_2\), PGE\(_{2\alpha}\), PGD\(_2\), TXB\(_2\)-all < 0.1%.

Because of the presence of human serum in samples of the TXB\(_2\) radioimmunoassay, a double antibody technique using goat anti-rabbit immunoglobulin (IgG) bound to beads (Immunobead second antibody, Bio-Rad Laboratories, Richmond, Calif.) was used. The TXB\(_2\) RIA using [PH]TXB\(_2\) (New England Nuclear, 150 Ci/mmol) and anti-sera at 1:4,800 was otherwise performed in the same way as the 6-keto-PGF\(_{1\alpha}\) radioimmunoassay described above. The range of sensitivity for TXB\(_2\) was 3–1,000 pg with 50% binding at 30–40 pg. Cross reactivities were as follows: PGE\(_1\)-0.6%, 0.06%, PGE\(_{2\alpha}\), 0.5%, PGE\(_1\), 0.2%; 6-keto-PGF\(_{1\alpha}\) and 6-keto-PGE\(_{1\alpha}\) both <0.02%; 13,14-dihydro 6,15-diketo-PGF\(_{1\alpha}\) both <0.02%.

Sample preparation for RIA. Samples were thawed and allowed to incubate at room temperature for 2 h. Dilutions were made as necessary with buffer I at the time of the assay. Results are expressed as nanograms of 6-keto-PGF\(_{1\alpha}\) per milliliter in each sample.

**Statistical analysis.** Statistical analysis was performed on an HP 9815 A computer (Hewlett-Packard Co., Palo Alto, Calif.) using prepared programs in volumes I and II of the HP statistics library (09815-15001) for the t test and two- and three-way analyses of variance (23).

**RESULTS**

NTG as a direct inhibitor of platelet aggregation. NTG inhibited platelet aggregation in vitro only at very high final concentrations. Table I summarizes a series of experiments in which PRP was preincubated for 1 min with NTG and compares the sensitivity of aggregation induced by various aggregating agents to the direct inhibitory effect of NTG. Whereas varying patterns of sensitivity of these agents to the inhibitory effect of NTG were noted, significant inhibition of aggregation occurred only at concentrations of NTG ≥ 100 ng/ml. NTG inhibition of aggregation was both time- and dose-dependent with longer incubations causing greater inhibition at any given NTG concentration ≥ 100 ng/ml (data not shown). This finding is in agreement with data recently published by Schafer et al. (4).

To determine whether NTG inhibited platelet TXA\(_2\) production, RIA for TXB\(_2\), the stable end product of TXA\(_2\), was performed on samples of PRP treated with various concentrations of NTG. The results are shown in Fig. 1. NTG caused a statistically significant decrease in TXB\(_2\) production only at concentrations of NTG ≥ 100 ng/ml, which as shown in Table I, parallels the inhibition of platelet aggregation. Studies in ASA-treated platelets demonstrated that NTG also inhibited primary phase aggregation induced by collagen, epinephrine, or U-44069 (data not shown). Thus, it is likely that NTG does not inhibit TXA\(_2\) synthesis directly, but rather the inhibition is secondary to some other platelet inhibitory effect.

As shown in Table I and Fig. 1 neither platelet aggregation nor TXB\(_2\) synthesis was significantly inhibited at concentrations of NTG < 100 ng/ml. How-

<table>
<thead>
<tr>
<th>Table I</th>
<th>Inhibition of Platelet Aggregation by Nitroglycerin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aggregating agent</td>
<td>NTG</td>
</tr>
<tr>
<td>ng/ml</td>
<td>% inhibition</td>
</tr>
<tr>
<td>10</td>
<td>0±0 (4)</td>
</tr>
<tr>
<td>100</td>
<td>2±5 (5)</td>
</tr>
<tr>
<td>1,000</td>
<td>89±3 (5)</td>
</tr>
<tr>
<td>10,000</td>
<td>100±0 (6)</td>
</tr>
<tr>
<td>50,000</td>
<td>—</td>
</tr>
</tbody>
</table>

After establishing the aggregation threshold for each agent, PRP was incubated for 1 min with NTG at the final concentrations listed. Results are expressed as percent inhibition of platelet aggregation compared to control without NTG. Numbers in parentheses indicate the number of samples tested. Inhibition was determined by method A for epinephrine and collagen and method B for AA, U-44069, and ADP (Methods). U-44069, the endoperoxide analog.

ever, after therapeutic cutaneous, sublingual, or intravenous administration of NTG in man, plasma levels of NTG peak below 10 ng/ml (24–28) except in severe congestive heart failure. Further, the only other clinical circumstance in which higher levels of NTG might be transiently achieved is during bolus infusion into coronary arteries during cardiac catheterization. Therefore, the direct inhibitory effect of NTG on platelet aggregation in vitro occurs only at suprapharmacologic concentrations, and with the exceptions noted, NTG concentrations achieved in vivo would not be expected to directly affect platelet aggregation or TXA₂ synthesis.

Inhibition of platelet aggregation by supernates from NTG-treated endothelial cells is related to enhancement of PGI₂ production. Fig. 2 displays the results of an individual experiment in which PRP was preincubated with supernates obtained from endothelial cells treated with NTG at pharmacologic concentrations and platelet aggregation then induced by adding collagen. A 3-min exposure of endothelial cells to NTG at clinically attainable concentrations of 0.1–10 ng/ml resulted in a dose-dependent production in the endothelial cell supernate of an inhibitor of platelet aggregation. The inhibition of platelet aggregation was seen at final concentrations of NTG in the PRP (1/10 the original concentration) that do not directly inhibit platelet aggregation, as demonstrated in the previous section.

RIA of each of the endothelial cell supernates for 6-keto-PGF₁α, the stable, spontaneous hydrolysis product of PGI₂, demonstrated a NTG dose-dependent increase in PGI₂ production by the endothelial cells (Fig. 2). For example, exposure of endothelial cells to 10 ng/ml NTG in buffer I for 3 min resulted in the production of 3.1 ng/ml 6-keto-PGF₁α, a 276% increase compared to the buffer control. This supernate caused a 97% inhibition of platelet aggregation. Lower doses of NTG elicited production of smaller amounts of 6-keto-PGF₁α and were associated with correspondingly lesser degrees of inhibition of platelet aggregation. Whereas control endothelial cells synthesized 1.16 ng/ml 6-keto-PGF₁α, this endothelial cell supernate did not inhibit platelet aggregation because the final concentration of PGI₂ in the aggregation cuvette is only 1/10 that in the endothelial cell supernate due to dilution. Thus, the concentration range of endothelial cell-synthesized PGI₂ (measured as 6-keto-PGF₁α) in these experiments that caused inhibition of platelet aggregation is very similar to that reported by others (10, 29) and also obtained by us using synthetic PGI₂ (see below).

As a control, cultured human lung fibroblasts (GM 1380) previously shown to be capable of synthesizing PGI₂ (11) were treated either with NTG or with AA in a manner identical to that for endothelial cells. The supernatant fluids from AA-treated fibroblasts

![Figure 1](image1.png)

**FIGURE 1** Inhibition of platelet TXB₂ production by NTG. PRP was preincubated with either buffer I alone or NTG at the concentrations listed for 1 min. Aggregation was then induced with a threshold dose of collagen. After 5 min, an aliquot of PRP was removed and analyzed by RIA for TXB₂. The results are expressed as a percentage of control in which no NTG was added (mean±SEM, n = 6–8 depending on concentration of NTG). Statistical analysis comparing the decrease in TXB₂ produced to controls was performed by Student's t-test. *P ≥ 0.0001.

![Figure 2](image2.png)

**FIGURE 2** Inhibition of collagen-induced platelet aggregation by supernates from NTG-treated endothelial cells is related to an increase in PGI₂ production. PRP was preincubated for 1 min with supernates from NTG-treated endothelial cells and collagen was then added (arrow). The concentration of NTG shown for each curve is that concentration used to treat the endothelial cells. The final concentration in the PRP (resulting from dilution of 50 μl of supernate into 450 μl of PRP) was 1/10 that shown. The curve labeled 0 ng/ml represents the effect of the supernate from endothelial cells incubated with buffer I containing lactose (used as the vehicle for NTG). This curve is identical to the control curve (not shown) containing no endothelial cell supernate. Samples of the endothelial cell supernates were also analyzed for 6-keto-PGF₁α by RIA. The results are listed and represent the concentration of 6-keto-PGF₁α in the endothelial cell supernate. The concentration of PGI₂ present in the PRP was 1/10 that shown due to dilution (see above).
inhibited platelet aggregation and contained 13 ng 6-keto-PGF$_{1 \alpha}$/10$^6$ cells as determined by RIA. However, fibroblasts treated with NTG did not inhibit aggregation and contained 1-14 pg 6-keto-PGF$_{1 \alpha}$/10$^6$ cells, which was not greater than the buffer control. This demonstrates that the response to NTG is not a general response of all cells capable of synthesizing PGI$_2$.

To verify that the inhibition of platelet aggregation by supernates of NTG-treated endothelial cells depends on the presence of PGI$_2$, a series of control experiments was performed. When endothelial cell cyclooxygenase was inactivated by pretreatment with 50 $\mu$M ASA for 2 h (16), production of the inhibitor elicited from endothelial cells by NTG was completely suppressed; RIA of the supernate showed that 6-keto-PGF$_{1 \alpha}$ production was inhibited by more than 95%. Inhibition of PGI$_2$ synthetase by preincubation of endothelial cells with 20 $\mu$g/ml 15-hydroperoxy-AA for 15 min also completely abolished production of the inhibitor and RIA of these supernates showed >85% inhibition of NTG-induced PGI$_2$ production. On the basis of these results, it is concluded that the inhibitory effect of the supernates of NTG-exposed endothelial cells depends on PGI$_2$. Furthermore, the inhibitor in these supernates was not generated by exposure to the endothelial cells to the buffer-vehicle alone and RIA demonstrated subinhibitory concentrations of 6-keto-PGF$_{1 \alpha}$ in these samples. Finally, NTG alone after incubation in buffer I in cell-free gelatin coated, medium conditioned wells did not inhibit platelet aggregation.

A heat lability study was performed to further characterize the inhibitor. Because it has been shown that endothelial cells incubated with AA produce PGI$_2$ (11, 17), we compared the decay rates at 37°C of inhibitors in supernates from endothelial cells treated with NTG or with AA. The decay rates of the two inhibitors of platelet aggregation were identical (data not shown), further suggesting that the inhibitor in NTG-treated endothelial cell supernates is PGI$_2$.

The dose-response relationship between NTG and 6-keto-PGF$_{1 \alpha}$ production by endothelial cells was obtained by combining the data from six separate experiments and is shown in Fig. 3. The amount of 6-keto-PGF$_{1 \alpha}$ produced was significantly greater than control ($P < 0.001$) at all NTG concentrations $\geq$0.1 ng/ml. For example, NTG 10 ng/ml increased 6-keto-PGF$_{1 \alpha}$ production by a mean value of 63%. Lower doses of NTG elicited production of smaller amounts of 6-keto-PGF$_{1 \alpha}$. Samples from these six experiments were also tested for the presence of PGI$_2$ biologic activity. Supernates from endothelial cells treated with NTG at concentrations $\geq$ 10 pg/ml incubated with PRP for 1 min significantly inhibited collagen-induced platelet aggregation ($P < 0.001$, $n = 10$). Similar inhibition was obtained using AA or epinephrine as the aggregating agents. As noted, pretreatment of the endothelial cells with either ASA or 15-hydroperoxy-AA completely abolished the production of the inhibitor of platelet aggregation and the production of 6-keto-PGF$_{1 \alpha}$.

To determine if there were any interactions between NTG, PGI$_2$, and endothelial cells that might have led to artifactual results in the RIA for 6-keto-PGF$_{1 \alpha}$, a series of recovery studies were performed. Synthetic PGI$_2$ (300–1200 pg/ml) was incubated in triplicate in cluster plates under four conditions: (a) in buffer I in cell-free wells; (b) in buffer I overlying ASA-treated endothelial cells; (c) in buffer I containing NTG at varying concentrations in cell-free wells; and (d) in buffer I containing NTG overlying ASA-treated endothelial cells. Recovery was virtually identical under the four conditions. When these data were analyzed by a three-way analysis of variance (the three factors being PGI$_2$, NTG, and ASA-treated endothelial cells), the only factor that significantly affected the amount of 6-keto-PGF$_{1 \alpha}$ recovered was the amount of PGI$_2$ added ($P < 0.0001$). Neither NTG ($P = 0.363$) nor the presence of ASA-treated endothelial cells ($P = 0.63$) altered the recovery of 6-keto-PGF$_{1 \alpha}$. Further, none of the possible two-way interactions nor the three-way interaction was statistically significant. Thus, neither NTG, endothelial cells, nor their combination caused
an alteration in immunologically assayable 6-keto-PGF1α.

Synergy of NTG and PGI₂ in the inhibition of platelet aggregation. It has recently been reported that NTG at suprapharmacologic concentrations (>1 μg/ml) is synergistic with PGI₂ in the inhibition of platelet aggregation in guinea-pig PRP (30). Therefore, we investigated the possibility that synergy was contributing to the inhibition of platelet aggregation in our experiments by studying the ability of combinations of synthetic PGI₂ and NTG to inhibit aggregation in PRP. When suprapharmacologic doses of NTG (>1 μg/ml) were combined with doses of PGI₂ that alone inhibited platelet aggregation 8–67% (0.6–1.5 nM or 0.21–0.52 ng/ml), the combinations synergistically inhibited platelet aggregation in six separate experiments (in all experiments the test for synergy (interaction by two-way analysis of variance was significant \( P < 0.01 \)). However, in five experiments, when NTG at pharmacologic doses (0.1–10 ng/ml) was combined with these concentrations of PGI₂, the combinations did not exhibit synergy in inhibiting aggregation. When these data were analyzed by two-way analysis of variance, the only significant factor affecting aggregation was the concentration of PGI₂ \( (P = 0.0001) \), five experiments). Neither NTG \( (P > 0.2) \), five experiments \) nor the interaction of NTG and PGI₂ \( (P = 0.06-0.92) \), five experiments \) altered the extent of aggregation. Thus, the inhibition of platelet aggregation caused by supernates of NTG-treated endothelial cells is not due to synergy between the NTG remaining in the supernate and the PGI₂ produced by the endothelial cells.

Because of the possibility raised in recent reports (31, 32) that platelets might be capable of metabolizing inactive 6-keto-PGF1α to the platelet inhibitor 6-keto-PGE1, we also investigated whether NTG interacted with 6-keto-PGF1α to inhibit aggregation. No inhibition of aggregation was noted when PRP was incubated either with 6-keto-PGF1α alone or with 6-keto-PGF1α and NTG for 1–30 min. This demonstrated that the inhibition of platelet aggregation by supernates of NTG-treated endothelial cells was not secondary to the conversion of 6-keto-PGF1α to some active inhibitory metabolite by the platelets.

DISCUSSION

In this paper, we have demonstrated that NTG at clinically attainable concentrations (0.1–10 ng/ml) induces a dose-dependent increase in endothelial cell PGI₂ production in vitro, as measured both by RIA for 6-keto-PGF1α and by inhibition of platelet aggregation. Pretreating the endothelial cells with either ASA or 15-hydroperoxy-AA blocked both the production of PGI₂ as measured by RIA and the inhibition of platelet aggregation. These results also demonstrate that the inhibition of platelet aggregation by these endothelial cell supernates was not due to adenosine, another platelet inhibitory metabolite (33) released from endothelial cells by various stimuli (34), because treatment of endothelial cells with aspirin has no effect on their release of adenosine (34, 35). Heating the endothelial cell supernates at 37°C, a condition known to inactivate PGI₂ but not other platelet-inhibitory prostaglandins such as PGE₁ or 6-keto PGE₁ (32, 36), inactivated the inhibitor. These experiments indicated that PGI₂ was the inhibitor of platelet aggregation present in the supernates of NTG-treated endothelial cells.

We have further demonstrated that the observed inhibition of platelet aggregation by these supernates is not due to synergy between PGI₂ and NTG remaining in the supernate, since PGI₂ and NTG synergistically inhibit platelet aggregation only at suprapharmacologic concentrations of NTG. Since this synergy is not present in vitro at clinically attainable concentrations of NTG, it is unlikely to be present in vivo after therapeutic administration of the drug.

The inhibition of platelet aggregation caused by the supernates of NTG-treated endothelial cells was rarely total. However, it has been estimated that the ratio of endothelial cells to platelets in the capillary circulation is ~1:1 (17). Our assay, because of a 1/10 dilution of endothelial cell supernatants, matches the products of 10⁴ endothelial cells with an average of 1.2 x 10⁴ platelets (300,000/mm·400 μl), yielding an endothelial cell to platelet ratio of 1:10,000. If the ratio had been that found in vivo, i.e., 1:1, the concentration of PGI₂ present would have been much higher and inhibition of platelet aggregation in vitro would have been complete, since even a twofold increase in PGI₂ would have totally inhibited platelet aggregation.

Several studies have been performed attempting to demonstrate that NTG induces the production of PGI₂ and other prostaglandins. Morcillo et al. (38) demonstrated that NTG, when infused into dogs, caused a decrease in coronary artery resistance which was accompanied by an increase in E series prostaglandins. Since indomethacin diminished both of these effects, it was suggested that NTG acted in part through the prostaglandin system. In contrast, Neichi et al. (39) were unable to demonstrate any effect of NTG (100 μg/ml) on PGI₂-TXA₂ synthesis using a coupled system of pig aortic microsomes and rat PRP. Forster (30, 40) while able to show that NTG (>1 μg/ml) caused an increase in coronary flow in isolated, perfused rat or guinea pig hearts, was unable to demonstrate an increase in PGI₂ in the coronary effluent. Finally, Feigen et al. (41) were unable to prevent canine renal artery vasodilation induced by bolus injection of extremely high doses of NTG (2–200 μg/ml) after pretreatment of the animal with indomethacin or meclofenamate. There are several possible reasons for these negative results. First, the suprapharmacologic concentrations of NTG used (>1 μg/ml) may
have been toxic. Second, there may be species differences with respect to the NTG-PGI₂ relationship.

Third, intact endothelial cells, rather than microsomes, may be required for the action of NTG to be expressed. Finally, it is critical to recognize that at high, suprapharmacologic concentrations, NTG may have a direct effect on vascular smooth muscle (42), which is not mediated by PGI₂ and is not seen clinically. This would be analogous to the direct inhibition of platelet aggregation by NTG at suprapharmacologic concentrations. Thus, the recent studies demonstrating that the plasma concentrations of NTG attained in man are 0.1 to 10 ng/ml (24, 28) necessitate a reexamination of much of the in vitro data on the possible mechanism of action of NTG.

Current evidence suggests that NTG relieves ischemia primarily by reducing cardiac work as a result of peripheral vasodilation rather than by directly affecting the coronary circulation (42–45). NTG may also relieve angina by causing relaxation of coronary artery spasm (46), and by shifting blood flow from normally perfused to ischemic myocardium in the absence of peripherally mediated hemodynamic changes (47).

We have shown that intact monolayers of human endothelial cells in vitro release PGI₂ in response to clinically attainable concentrations of NTG. The PGI₂ produced inhibits platelet aggregation. These data suggest that the vasodilating properties of NTG noted above are, at least in part, indirect and due to the induction by NTG of endothelial cell PGI₂ synthesis. The mechanism by which PGI₂ induces vasodilation is unclear, though it may be related to its ability to alter cyclic nucleotide levels and calcium ion fluxes (48). Studies attempting to relate the direct effect of NTG to such alterations have thus far been inconclusive (49–54).

In conclusion, current available data suggest that the mechanism of NTG-induced vasodilation is multifactorial. The findings described here provided a basis for understanding in part how NTG might relieve myocardial ischemia by altering the PGI₂:TXA₂ ratio in favor of PGI₂ excess with resultant vasodilatation and inhibition of platelet function.

ACKNOWLEDGMENTS

We wish to express our appreciation to Charles Dorso and Sheldon Brown for technical assistance and to Naomi Nemtrow and Pauline Santos for preparation of the manuscript.

REFERENCES


